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Abstract
Background: This study aimed at analyzing the economic burden and disease-specific health-related quality of life
(HRQOL) of patients with spinal muscular atrophy (SMA) in Germany. SMA is a so far non-curable neuromuscular
disease of the anterior nerve cells that causes high rates of morbidity and mortality.
Methods: In a cross-sectional study we analyzed the cost of illness (COI) and factors that influence the direct, indirect
and informal care costs of affected patients and their families by using standardized, self-developed questionnaires.
We used the PedsQL™© Measurement Model to analyze the disease-specific HRQOL of patients.
Results: One hundred eighty nine patients with SMA types I to III aged <1 to 73 years were enrolled. The average
annual COI was estimated at €70,566 per patient in 2013. The highest cost resulted in SMA I with significant lower
costs for the milder phenotypes. Inversely, the self-estimated HRQOL increased from SMA I to SMA III. Major cost drivers
were informal care cost and indirect cost incurred by patients and their caregivers.
Conclusions: Although SMA requires high standards of care, there has been a distinct lack of health services research
on SMA. Accordingly, our results significantly contribute to a more comprehensive insight into the current burden of
SMA and quality of life status as related to SMA health services in Germany. In the light of innovative therapeutic
interventions, our results suggest a notable potential for a reduction in overall COI and improvement of HRQOL if the
therapeutic intervention leads to a less severe course of the disease.
Keywords: Spinal muscular atrophy (SMA), Health-related quality of life (HRQOL), Direct cost, Indirect cost, Informal
care cost, Cost of illness (COI), Health care burden, Neuromuscular disease, Health services research
Background
Spinal muscular atrophy (SMA) is an autosomal reces-
sive, inherited neuromuscular disease that affects the
spinal anterior nerve cells. It leads to predominantly
proximal muscle and diaphragm weakness and paralysis,
along with respiratory distress, progressive disability,
reduced working capacity and high health care needs.
Infantile forms significantly reduce life expectancy [1, 2].
In >90 % of cases the disease is caused by homozygous
deletions within the survival motor neuron 1 (SMN1)
gene on chromosome 5q13 [3]. SMA caused by SMN1
deletions is usually classified into three phenotypes
characterized by age of onset and the best motor func-
tion achieved. SMA type I (Werdnig-Hoffmann) is the
most common and severe subtype, and SMA type III
(Kugelberg-Welander) with onset >18 months and
achievement of independent walking represents the
mildest one [4]. SMA is so far not curable; and patients
need long-term symptomatic multidisciplinary medical
care to maintain mobility, independency, ventilation and
nutrition [5]. Living with SMA is challenging not only
for patients but also for their families and caregivers, as
well as medical personnel and the society. Economic
analyses and health services research for SMA have not
been conducted in any great detail to date, but are
urgently needed with regard to emerging innovative
therapies. To be able to compare health care expendi-
tures for the current symptomatic treatment and care
with costs of future curative therapies, cost evaluations
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are mandatory. Our study provides a detailed analysis of
the cost of illness (COI) of SMA, differentiating between
the SMA subtypes in Germany. However, the burden of
SMA cannot be reduced to an analysis of cost items
only. Considering the disease-specific challenges and the
individual burden it is also necessary to analyze important




We conducted a Germany-wide cross-sectional study
over a four months period from April to August 2013.
Disease- and subtype-specific standardized question-
naires were self-developed in focus groups with input
from clinicians, health-economists and patient represen-
tatives. The questionnaire comprised 109–123 items
(depending on SMA type and respondent – patient or
caregiver) including socio-demographic data, current/
past occupation, health status and use of medical and
care resources. For assessment of COI, respondents were
asked to recall the consumption of resources over an
exact time-period (e.g. drug treatment in the last week,
hospitalizations within the last three months, construc-
tional modifications since disease onset). The question-
naire had been utilized and pretested (n = 10) in a
previous study assessing the health care burden of
Duchenne muscular dystrophy (DMD) [6]. For assess-
ment of the disease burden, we also analyzed the dis-
ease-specific HRQOL of patients either self- or proxy-
reported by the Pediatric Quality of Life Inventory™©
(PedsQL™©), module for neuromuscular disorders,
German version 3.0. This questionnaire was developed by
Dr. James W. Varni [7, 8] and was translated into German
by the Mapi Research Trust. The PedsQL™© includes three
major disease-related sections (‘problems with the neuro-
muscular disease’, ‘communication’ and ‘family resources’).
The score had been validated for children and young
adults (13–18) with SMA before [9–11]. However, we also
utilized it in our adult patients, thereby ensuring best pos-
sible comparability of results. Patients with a genetically
confirmed SMA (n = 265) were identified via the German
SMA patient registry (www.sma-register.de), which was
established within the network of excellence TREAT-
NMD (www.treat-nmd.eu) in 2008 [12]. The paper-
based questionnaire was distributed by post. For
patients <16 years of age and/or highly care
dependent patients, their caring relative or parent an-
swered the questionnaire.
Standard protocol approvals, registrations and patient
consents
Patients and legal guardians/parents, respectively, gave
their written consent to participate in this study,
including the option of data withdrawal. The ethics
board of the Ludwig-Maximilians-University of Munich
approved the study.
Data analysis
We retrospectively evaluated the total COI, comprising
direct, indirect and informal care costs of individual
patients and their families. Direct costs comprise the
monetarily assessed disease-specific consumption of
medical and non-medical resources (COR) [13]. Non-
medical disease-specific costs include disease-related
travel expenses, costs for legal advice and constructional
modifications for example. Costs of hospitalization, drug
treatment, rehabilitation services (e.g. physiotherapy,
occupational therapy), medical aids and ventilation were
aggregated as direct medical COI. The COR was
assessed monetarily using empirical standard cost for
Germany [14, 15], official price lists [16] and patient re-
ported data such as cost for constructional modifica-
tions, legal advice or cost for housing. By anticipating a
stable demand for health care resources, we estimated
mean direct cost per year.
Informal care costs represent time spent for care by
relatives, whereas indirect costs are productivity losses
to society due to absenteeism, invalidity or premature
death [13]. As these cost components are closely related,
we analyzed informal care cost for non-working parents
only to prevent double accounting of loss of productivity
and care times of working parents. To analyze the
indirect COI, we assessed the employment status of
patients and parents/caregivers and evaluated disease-
related productivity losses of patients and/or parents
by considering absenteeism, invalidity or changes in
their working situation.
Cost was estimated in Euros for 2013. Statistical
analyzes were conducted using SPSS® test procedures
(Mann–Whitney-U; T test). We only included complete
and nearly complete questionnaires; any missing values
were marked and excluded from the particular analysis.
Results
Demographics
One hundred eighty nine out of 265 invited SMA
patients/parents were enrolled in this study (response
rate 71 %). Patients had a median age of 19 years (range
0–73; Table 1); 59 % of the patients were male. All pa-
tients with SMA I and the vast majority of those with
SMA II (92 %) and III (89 %) were covered by a statu-
tory health insurance, in line with the typical distribution
within the German population [17]. Differences between
SMA types were seen in patients’ characteristics such as
family status, education level, employment status and
care level1 (Table 2). The majority of patients quit work
or reduced working time when their best self-reported
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motor performance was reduced to sitting (SMA II:
100 %; SMA III: 39 %) or when walking became
impaired (SMA III: 61 %, data not shown). Further-
more, parents of more severely affected children had
to quit their jobs or reduce working times more
frequently, which resulted in lower gross salaries per
year (Table 2).
Table 1 Patient demographics: Response rate, age and
SMA-related characteristics
SMA subtype
Total I II III
Response rate
Total patient number 265 20 115 130
Enrolled respondents 189 12 73 104
Response rate [%] 71 60 63 80
Ratio of patients/parents
among respondents [%]
52/48 0/100 30/70 74/26
Age of enrolled patients
Min. [years] 0 0 2 2
Max. [years] 73 7 56 73
Median [years] 19 1 11 33
Current motor function
N 177 9 69 99
Walk [%] 33 0 0 59
Sit [%] 47 11 65 38
None [%] 20 89 35 3
Wheelchair use
N 154 4 51 99
Always [%] 61 50 100 41
Sometimes [%] 14 0 0 21
None [%] 25 50 0 37
Feed tube use
N 177 9 69 99
Yes [%] 6 22 10 1
No [%] 94 78 90 99
Spine surgery
N 176 9 68 99
Yes [%] 23 0 22 8
No [%] 153 100 78 92
Non-invasive ventilation
N 174 9 69 96
Always [%] 1 0 1 0
Sometimes [%] 12 22 22 4
None [%] 87 78 77 96
Invasive ventilation
N 174 8 69 97
Always [%] 1 13 0 0
Sometimes [%] 0 0 0 0
None [%] 99 88 100 100
Differentiation by SMA subtypes (I = Werdnig-Hoffmann, II = intermediate,
III = Kugelberg-Welander). This differentiation into subtypes is used for all
following tables and figures. SMA-related characteristics of enrolled patients
(motor function, spine surgery, use of wheelchair, feed tube use and ventilation)
originate from the German SMA registry at the time of execution. Because of
rounding, percentages might not add up to exactly 100 %. N = number of patients
Table 2 Patient demographics: Family status, education,
employment status and patient care levels
Patients Parents
I II III I II III
Family status [%]
Widowed - 0 1 - 2 -
Divorced - 0 11 - 6 11
Married - 5 33 75 75 78
In a partnership - 18 9 17 16 11
Unmarried - 77 46 8 2 -
Education [%]
No qualification - - 3 - 2 4
School - 73 63 75 62 70




- 60 79 92 92 85
Employment
status [%]
Non-working - 52 26 - 6 7
Currently working
Self-employed - - 4 18 4 -
Employed - 38 49 27 60 74
Reduced working
time
- 13 21 100 58 10
Quit working life - 10 21 55 29 19
Care levels [%]a
No care level 20 1 37 - - -
Care level 1 10 12 20 - - -
Care level 2 20 27 31 - - -
Care level 3 50 59 13 - - -
Gross salary per











These demographic parameters served as a basis for the indirect cost calculation
of patients and their parents. The classification into care levels (level 1–3)
represents the individual classification within the German health care system; a
higher number indicates greater needs (acare level 1: at least 90 min/day of
which at least 45 min account for basic care needs (personal hygiene, feeding,
mobility); care level 2: at least 3 h/day of which at least 2 h account for basic care
needs; care level 3: at least 5 h/day of which at least 4 h account for basic care
needs [36]). Patients/parents collated in the category ‘quit working life’ quit their
working lives due to the disease. Those who are ‘non-working’ additionally
represent pensioners, trainees and students. Data is presented as % or mean
(SD). Lines indicate not applicable answers. Because of rounding, percentages
might not add up to exactly 100 %
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Direct COI
The direct medical COI was analyzed based on the COR
of every individual patient. SMA I patients displayed the
highest COR, mainly in form of outpatient medical
consultations, in-patient treatment and artificial nutri-
tion (Fig. 1). Less severely affected patients showed a
decrease in the COR; however, utilization of sleep
laboratory diagnostics, drug treatment, medical aids and
respiratory management were most prominent in SMA
II, and the highest need for psychological assistance was
seen in SMA III.
Based on the COR, the total annual direct medical
COI was estimated at a mean of €14,342 per patient
(20 % of total COI) with significant differences between
the SMA subtypes. The direct medical COI was more
than three times higher in SMA I (€53,707/y per patient)
than in SMA II and III (€15,305/y and €9,125/y per
patient resp., p < 0.001). SMA I patients produced the
highest cost in nearly all assessed categories (apart from
medical aids and attendance in rehabilitation programs).
Costs for inpatient medical treatments and for medical
aids (8 % and 5 % respectively of total COI) were identified
as the main cost drivers.
In contrast, direct non-medical COI (e.g. care cost,
disease-related investments) was about 2.8 times higher
than the mean direct medical COI (€40,378/y per pa-
tient, 58 % of total COI, Table 3). Direct non-medical
cost was most prominent in SMA II with significant
differences between SMA I/II and SMA III (p < 0.05).
Informal care was the most important non-medical
cost driver in all SMA subtypes (29 % of total COI).
Total overall care effort was estimated at 7.8 h/day
(of which parents provided 7 h/day) and turned out
to be most relevant in SMA I (15 h/day; SMA II:
11 h/day; SMA III: 4 h/day). Mainly parents (69 %)
and partners (21 %, not in SMA I) provided informal
care. While informal care costs decreased from SMA
I to III, total mean direct non-medical COI increased
from SMA I to SMA II due to higher costs for housing,
personal assistance and constructional modifications in
SMA II.
In total, overall mean direct COI added up to €54,721/y
per patient with significant differences between the SMA
subtype I (€99,664/y per patient) to III (€36,064/y per
patient, p < 0.001) and SMA II (€73,911/y per patient) to
SMA III (p < 0.001, Table 3).
Indirect COI
The indirect COI reflects the economic loss of prod-
uctivity of patients and/or their parents caused by
absenteeism, invalidity or changes in their working
situation. Overall mean annual indirect COI added up
to €15,845 per patient (Table 3). The highest product-
ivity loss was found in SMA III patients. Parents
seemed to be more limited in their careers and their
productivity in SMA I and II caused by the patients’
younger age at disease manifestation.
Fig. 1 Consumption of resources (COR) of direct medical services of SMA patients. The COR of direct medical services is differentiated by SMA
subtypes and shown in % of total patients. *Collated as ‘outpatient medical cost’. #Collated as ‘inpatient medical cost’
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Total economic burden
Taking all described cost factors into account, the overall
mean total COI was estimated at €70,566/y per patient.
The most relevant disease burden was found in SMA I
(€107,807/y per patient) with a decrease towards SMA II
(€90,267/y) and SMA III (€52,440/y, Table 3) and a
significant difference for SMA I and II compared to
SMA III (p < 0.05). Using recent prevalence data from
Northern England [18], we approximated the total
economic burden caused by SMA in Germany at €106.2
million with the highest prevalence-based societal
burden in SMA II (€41.4 million/y, Table 4).
Disease-specific health-related quality of life (HRQOL)
Patients with SMA III assessed their disease-specific
HRQOL as fairly high (self-reported), while SMA I
patients had a low proxy-assessed HRQOL (69 vs. 34 on
a scale with 0 =min. and 100 =max.; p < 0.001, Fig. 2a).
We did not see any significant differences in the self- or
proxy-evaluation of HRQOL in SMA II and III (p > 0.05).
The most severe handicaps (along with lower scores) were
identified in the qualitative test dimensions ‘problems with
the neuromuscular disease’ and ‘problems with family
resources’, while ‘communication’ was not so severely
impaired (Fig. 2b). In all test dimensions, the scores
increased from SMA I to III, indicating an increasing
disease-specific HRQOL.
Discussion
In this study, we performed a comprehensive analysis of
the disease burden in SMA by evaluating direct and
indirect cost as well as the disease-specific HRQOL. Our
results revealed a mean direct COI of €54,721/y per pa-
tient which was about 14 times higher than the average
health expenditure per patient in Germany in 2013 [19].
The highest overall demand for medical and care
services was identified in SMA I, resulting in signifi-
cantly higher cost compared to that of SMA II and III.
Nevertheless, SMA I patients utilized respiratory devices
and sleep laboratory tests to a lower extent than SMA II
patients. Although respiratory failure is the most
frequent cause of death in these young children [4], we
Table 3 Cost of illness (COI) per patient for SMA [in €/y]




Outpatient medical costs 331 (579) 0 % 463 (455) 392 (496) 274 (640)
Inpatient medical costs 5,634 (24,193) 8 % 39,972 (81,057) 4,454 (11,892) 2,488 (10,730)
Rehabilitation costs (in-/outpatient) 822 (3,535) 1 % 594 (2,059) 971 (3,901) 745 (3,423)
Drug treatment costs 189 (527) 0 % 389 (1,232) 245 (563) 126 (334)
Costs for use of rehabilitation services 2,050 (2,094) 3 % 3,488 (4,734) 2,149 (1,641) 1,814 (1,849)
Costs for artificial nutrition 243 (1,157) 0 % 1,940 (3,351) 247 (1,139) 90 (573)
Costs for medical aids 3,451 (2,450) 5 % 1,648 (1,628) 4,385 (2,133) 3,003 (2,508)
Costs for respiratory management 1,678 (2,760) 2 % 5,698 (5,882) 2,548 (2,280) 594 (1,713)
Total direct medical COI 14,342 (26,379) 20 % 53,707 (81,809) 15,305 (14,220) 9,125 (14,330)
Costs for housing 12,854 (38,639) 18 % 10,160 (26,569) 20,001 (50,000) 8,173 (29,107)
Costs for personal assistance for school and work attendance 2,162 (6,694) 3 % 0 4,301 (9,513) 958 (3,794)
Travel expenses 2,800 (6,637) 4 % 2,068 (1,866) 2,040 (2,525) 3,424 (8,661)
Informal care costs 20,170 (28,924) 29 % 31,542 (22,541) 28,571 (35,107) 12,902 (22,173)
Costs for legal advice 9 (37) 0 % 0 12 (37) 8 (39)
Costs for constructional modifications to house 1,860 (3,408) 3 % 833 (2,887) 2,882 (4,511) 1,254 (2,133)
Costs for constructional modifications to automobile 1,116 (2,577) 2 % 1,455 (4,824) 1,751 (3,252) 601 (1,193)
Other expenditures 129 (782) 0 % 20 (69) 110 (847) 156 (783)
Total direct non-medical COI 40,378 (47,464) 58 % 45,957 (39,044) 58,607 (54,214) 26,940 (38,381)
Total direct COI 54,721 (59,210) 78 % 99,664 (104,071) 73,911 (60,597) 36,064 (42,753)
Indirect cost patients 20,275 (22,857) 29 % 0 17,016 (18,782) 20,906 (23,645)
Indirect cost parents 13,204 (17,264) 19 % 13,959 (11,582) 19,034 (19,891) 4,195 (9,637)
Total indirect COI 15,845 (20,067) 22 % 8,143 (11,173) 16,356 (18,971) 16,376 (21,511)
Total COI 70,566 (62,725) 100 % 107,807 (102,082) 90,267 (65,467) 52,440 (48,000)
Data presented as mean (SD) in 2013 in € per year. Because of rounding, percentages might not add up to exactly 100 %. Costs for housing include e.g. professional
care, domestic aids; other expenditures comprise patient-reported data for expenditures such as for special clothes for wheelchair users, podologic care etc.
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found that not all of them were ventilated, which is in
line with the patient characteristics within the German
SMA registry (Table 1). The low ventilation rates in
SMA I patients in Germany could be attributed to differ-
ences regarding the availability of expert SMA treatment
centers, or different preferences of physicians and
parents towards ventilation [12]. The use of medical aids
seemed to be of secondary importance in SMA I, maybe
due to the reduced physical development of SMA I pa-
tients. More importantly, this result might even suggest
a possible shortage of medical aids (e.g. care aids or
adapted beds) for this age group. The results of our
study contribute to the transparency of the current con-
sumption of resources of SMA patients in Germany.
The use of psychological assistance turned out to be low
in general, although previous publications showed a
need not only for patients but also for the parents faced
with a devastating disease affecting their kids [20].
Moreover, access to inpatient and outpatient rehabilita-
tion programs seemed to be low, possibly revealing a
supply gap in specialized rehabilitation centers.
As far as we know, this is the first study conducting a
detailed health services evaluation to investigate the
economic burden of SMA in Germany. Larkindale et al.
analyzed the COI of different neuromuscular diseases
(SMA, ALS, DMD, DM) in the US in 2010. However,
COI results for SMA were not mentioned in the publica-
tion due to the small sample size and difficulties in an
adequate classification of SMA subtypes [21]. This em-
phasizes the need for a detailed analysis of a genetically
defined and comprehensively diagnosed group of SMA
patients and highlights the importance of our study.
Nevertheless, the results for SMA were published online
by the US muscular dystrophy association (MDA). In
contrast to our findings, higher costs were found in the
patient group with diagnosis before/at age 3 ($184,647
per patient), but lower costs for patients with later onset
($45,750 per patient) [22]. These discrepancies may
result from (1) differences in the origin of data (com-
mercial, Medicare, patient-reported), (2) the definition of
different subgroups (age at diagnosis vs. defined SMA
subtypes), (3) the methodological differences in valuing
COR, (4) general disparities between the US and
German health care systems, e.g. incentives for both
health care providers and patients or compensation
systems, (5) differences in standards of care as recently
analyzed by Bladen et al. [12] and (6) the varying charac-
teristics of the populations with regard to morbidity and
Table 4 Total economic burden in Germany
SMA subtype
Total I II III
Prevalence [per 100,000] [18] 1.87 0.10 0.57 0.64
Total German population[in 2013] [37] 80,511,300
Approx. patient number in Germany [in 2013] 1,506 81 459 515
Total COI per patient [in €/y] 70,566 107,807 90,267 52,440
Total national cost [in €/y] 106,241,507 8,679,665 41,424,872 27,021,093
National economic burden is based on prevalence data applying to Germany in 2013. Costs are presented in € for the year 2013
Fig. 2 Disease-specific health-related quality of life (HRQOL) of SMA patients. Disease-specific HRQOL was assessed by PedsQL™© Measurement
Model, module for neuromuscular disorders, German version 3.0. Higher scores indicate better HRQOL. HRQOL was either patient self-reported or
proxy-reported (a) and subdivided into the disease-specific sections: problems with the neuromuscular disease, communication and family resources
(b). Mean scores are presented with standard deviations. Scale with 0 =min. and 100 =max. * indicates significant differences (p < 0.001)
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demography. These factors may influence country-specific
COR and resulting cost and therefore limit the transfer-
ability and comparability of results between different
countries [23]. That is precisely why our findings cannot
easily be translated to other countries or other diseases.
Nevertheless, the MDA study roughly confirms our results
of higher cost in SMA I/SMA with early onset, which re-
sult from the higher level of COR and the care needed by
these severely affected patients [22]. We previously re-
ported similar results for dystrophinopathies in Germany
and showed that health care expenditures increased with
the progression of the disease and the increasing loss of
an individual’s self-dependency [6].
According to our results, SMA type I patients caused the
highest informal care cost, reflecting both the severity of
the disease and greater need for care. SMA I patients typic-
ally have a drastically shortened life expectancy of <2 years
[24, 25]. Even healthy babies and young children are de-
manding with regard to the attention and care that needs
to be provided by the parents. Although we have assessed
the informal care along with its cost in SMA, the compar-
ability regarding the effort which is usually devoted to
healthy children remains limited because of lack of publi-
cations in this field. Recently, COI analyses assessed infor-
mal care as a main cost driver in neuromuscular diseases,
showing an increasing loss of family income together with
increasing care need and dependency [6, 21, 26]. These
findings fully apply to SMA. We found that a high propor-
tion of working parents (esp. of SMA I patients) had to re-
duce or even quit their jobs to be able to care for their
affected child, leading to a reduced family income. We esti-
mated the average annual informal care cost per patient at
€20,170. Since we excluded working parents from our care
cost estimation to prevent double counting of indirect cost
and informal care cost, our results may even underestimate
real care expenditures (for example, the average annual in-
formal care cost per patient including working and non-
working parents is much higher at €34,871). Besides care
cost, indirect cost was previously described as a major cost
driver in dystrophinopathies [6, 26] and our results show
similar findings in SMA. We estimated that indirect cost
was most prominent in SMA II and III due to the loss of
productivity of patients and/or their parents. Moreover,
partners took over a major part of care in the group of
adult patients, mainly in SMA III. Since we only analyzed
the employment status of the patient itself or of one
parent, indirect cost may be much higher when taking the
second parent and/or other family members into account.
Altogether, we estimated a total economic burden of
€106.5 million per year in Germany using prevalence
data from Northern England [18]. Obviously, more pre-
cise assessments of country-specific epidemiologic data
are urgently needed. One major step might be the imple-
mentation of patient registries in rare diseases like SMA.
For this study, we utilized the German SMA patient
registry (www.sma-register.de) [12] resulting in a re-
sponse rate of >70 %, which is a very good result for a
cross-sectional study dealing with sensitive areas of life
such as cost, handicaps and individual problems.
Patient-reported outcomes (PRO) as HRQOL help to
understand the perceived health state from a patient per-
spective, e.g. the individual impairment resulting from
symptoms and disabilities, and reveals impacts on other
dimensions of independent living [27]. Particularly in
chronic diseases, HRQOL results can illustrate needs and
shortcomings in health care, hopefully leading to improve-
ments in services for adult [28] and pediatric/adolescent
patients [29, 30]. In our study, HRQOL increased from
SMA I to the milder SMA III phenotype, which is consist-
ent with the results of a previous study in SMA II and III,
in which a higher HRQOL in SMA III compared to SMA
II had been shown [31]. Interestingly, in a Brazilian study,
the self-reported HRQOL of children with SMA II/III
(aged >4y) was irrespective of motor ability and SMA sub-
type (SMA II: 55.85 vs. SMA III: 52.94) [32]. However,
they utilized the Autoquestionnaire Qualité de Vie Enfant
Imagé (AUQEI) to assess HRQOL, a generic tool covering
function, family, leisure, autonomy and other parameters,
while we used the disease-specific instrument PedsQL™©to
better determine differences between the SMA sub-
types. Additionally, the assessment of different
disease-related dimensions allows for a more precise
comprehension of the important problems of patients
in their daily lives. Thus, SMA had the most import-
ant impact on the dimensions ‘problems with the
neuromuscular disease’, which encompasses disease-
associated handicaps, and, secondly, ‘family resources’,
which is related to familial financial and social as-
pects. The results of our study are confirmed by the
results of a recent investigation in the Czech Republic
in which the disease-specific HRQOL in SMA pa-
tients aged 3–18 years was similarly analyzed with the
PedsQL™© 3.0 Neuromuscular Module [33].
A potential limitation of our study might be a bias due
to the utilization of a SMA patient registry to recruit
study participants. Patients and families join the registry
voluntarily; therefore, highly compliant and dedicated
participants may be overrepresented. Furthermore,
although SMA I is the most common SMA subtype, the
life expectancy of patients is very limited. Given the low
prevalence and small number of cases in this subgroup,
our cost data for SMA I must be seen against this back-
ground. Additionally, in a retrospective study, recall bias
may be a systematic error when estimating COI based
on patient reported data from the past. Moreover, we
used minimum prices to estimate the economic burden,
possibly leading to the underestimation of the exact
COI, and as mentioned above, the indirect cost may be
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much higher particularly when taking the impact on
more than one family member into account.
In summary, our study provides the first comprehensive
economic analysis of SMA in Germany from the perspec-
tive of patients, their families and society. Different in-
novative therapies are currently being investigated ‘from
bench to bedside’, e.g. gene therapy, molecular therapy
with antisense oligonucleotides, and small molecules,
which hopefully will soon be available to treat this devas-
tating disease [34, 35]. In this context, our study results
show that new innovative therapies modifying the severity
of SMA into a milder phenotype have the potential to
reduce COR together with COI. However, innovative ther-
apies may go hand in hand with high cost due to research
and particularly clinical development activities. Consider-
ing this, a precise estimation of overall cost is not feasible.
Modifying the severity of SMA towards a milder pheno-
type may be connected with improvements in patients’
quality of life. Although COI in SMA II was seen to be
almost as high as in SMA I, SMA II patients showed a
significantly higher quality of life. This further underlines
the huge need for early-stage treatment and adequate
support to reduce COR and to improve HRQOL.
Conclusions
We analyzed the disease burden of SMA in Germany
from a health economic perspective. This study is highly
important for patients, families and caregivers as well as
for the pharmaceutical industry. Concerning emerging
therapies, giving equal priority to assessing the clinical
and health economic situation may facilitate the transla-
tion of clinical research results into clinical practice. Im-
portantly, our study contributes to a more comprehensive
understanding of health care delivery issues related to
SMA and neuromuscular diseases in general.
Endnotes
1In Germany, the long-term care insurance is classified
into three levels of care, thereby reflecting the grade of
required personal care. Care allowance for at-home care
delivered by relatives in 2013/2014 is calculated with
€305, €525 and €700 per month for care level I, II and
III, respectively. Alternatively, care rendered by profes-
sional care givers is covered by €665, €1,250, €1,550 and
€1,918 per month for care level I, II, III and cases of
hardship respectively [38].
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